Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

Total Revenues in 2023 were $93.4 million, up 10$48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of$18.9 million, up by 37% from the same period last yearAlvotech's Simlandi™ biosimilar to Humira® (adalimumab) was approved in the U.S. as the first high-concentration biosimilar with interchangeable statusSales of Alvotech's Jamteki™ biosimilar to Stelara® (ustekinumab) started in Canada with launches expected in Japan in Q2 and ...